« previous next »
Pages: [1]   Go Down

Author Topic: New analysis confirms canagliflozin's cardiovascular and kidney benefits in older adults  (Read 26 times)

Ketua Dobbs

  • Administrator
  • Rank: Jr. Consultant
  • *****
  • Posts: 694
  • Ketua
    • DOBBS
  • Field of Practice: CLINICAL HAEMATOLOGY
  • State: Selangor
New analysis confirms canagliflozin's cardiovascular and kidney benefits in older adults
« on: October 28, 2024, 01:32:10 AM »
New analysis confirms canagliflozin's cardiovascular and kidney benefits in older adults

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients' age.
Source: New analysis confirms canagliflozin's cardiovascular and kidney benefits in older adults
Logged
Let's make Bulletin Boards great again

Doctors Only Bulletin Board System (DOBBS)

New analysis confirms canagliflozin's cardiovascular and kidney benefits in older adults
« on: October 28, 2024, 01:32:10 AM »
Pages: [1]   Go Up
« previous next »
 


Powered by EzPortal